Lentivirally Redirected CD123 Autologous T Cells in AML
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Sponsor: University of Pennsylvania
A PHASE1 clinical study on Acute Myeloid Leukemia, Adult and Acute Myeloid Leukemia, Refractory, this trial is ongoing. The trial is conducted by University of Pennsylvania and has accumulated 14 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Jul 2025 — Present [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Jul 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Sep 2023 — May 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 9 earlier versions
-
Jul 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
-
Apr 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE1
-
Jan 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE1
-
Jul 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1
-
Feb 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jan 2020 — Mar 2020 [monthly]
Recruiting PHASE1
-
Jan 2019 — Jan 2020 [monthly]
Recruiting PHASE1
First recorded
Dec 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .